← Back to Search

Other

TL-925 for Allergic Conjunctivitis

Phase 2

Recruiting

Research Sponsored by Telios Pharma, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3, 5 and 7 minutes after cac

Awards & highlights

Study Summary

This trial studies a drug (TL-925) to treat allergic conjunctivitis. 70 people will get the drug or a placebo and be monitored for effectiveness.

Who is the study for?

This trial is for adults over 18 with a history of eye allergies confirmed by a skin test. They must have good vision and react to an allergen challenge in both eyes. Participants should not have any other eye diseases, recent eye surgeries, or infections.Check my eligibility

What is being tested?

The study tests TL-925 against a placebo in the form of eye drops for allergic conjunctivitis. It's randomized, meaning people are put into the TL-925 or placebo group by chance, and neither they nor the researchers know who gets what (double-masked).See study design

What are the potential side effects?

While specific side effects aren't listed here, typical reactions to ophthalmic drugs can include temporary discomfort, redness or itching in the eyes, possible blurred vision or watery eyes immediately after use.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3, 5 and 7 minutes after cac

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3, 5 and 7 minutes after cac

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3, 5 and 7 minutes after cac for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Conjunctival redness

Ocular itching

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: TL-925 ArmActive Control1 Intervention

Subjects will be dosed in clinic on days of dosing.

Group II: Placebo ArmPlacebo Group1 Intervention

Subjects will be dosed in clinic on days of dosing.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Telios Pharma, Inc.Lead Sponsor

9 Previous Clinical Trials

1,337 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still availability to join this research as a participant?

"According to clinicaltrials.gov, this research study is looking for suitable participants. The trial was initially introduced on November 1st 2023 before receiving its last update in late November the same year."

Answered by AI

Is TL-925 Arm a viable option for risk mitigation?

"The safety rating of TL-925 Arm is a 2, since it has only entered Phase 2 trials and there is no data yet confirming efficacy."

Answered by AI

What is the total count of participants in this medical experiment?

"Correct. According to clinicaltrials.gov, this medical trial initiated recruitment on November 1st 2023 and is still currently in progress as of the 29th of November 2023. As such, 70 individuals are needed for the study across a single location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of TL-925 for the Treatment of Allergic Conjunctivitis

2023. "A Study of TL-925 for the Treatment of Allergic Conjunctivitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06153342.